Johns Hopkins Publishes Clinical Results on Stereotactic Ablative Radiotherapy Monotherapy Inducing Anti-Cancer Immune Response in Non-Small Cell Lung Cancer
Immune-Inducing Mechanism of Stereotactic Ablative Radiotherapy
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University has published the results of a prospective clinical trial (NCT03603002) on the effects of stereotactic ablative radiotherapy (SABR) monotherapy on the immune system of six patients with stage I non-small cell lung cancer (NSCLC). This study goes beyond simply physically destroying tumors and aims to elucidate how radiation therapy induces immune responses through precise genomic and T-cell analysis. By comparing pre- and post-SABR treatment biopsy tissues and blood samples, the researchers confirmed that radiation promotes immune-mediated tumor recognition. This suggests that radiation may act as an endogenous vaccine in patients with early-stage lung cancer who are not candidates for surgery.
Immune Activation Demonstrated Through T-Cell Receptor Sequencing
The research team analyzed changes in the tumor microenvironment using MANAFEST, a method for analyzing functional T-cell expansion associated with neoantigens, and T-cell receptor (TCR) sequencing. As early as 5-7 days after irradiation, a significant increase in the infiltration of CD8+ T cells, which have anti-cancer activity, was observed within the tumor, and expansion of tumor-specific T-cell clones was observed. This prospective data, at the molecular level, demonstrates that SABR triggers a systemic immune response by releasing tumor neoantigens during the process of cancer cell death. Despite being a small clinical trial with only six patients, it clearly demonstrates the immune cell activation pathway and has garnered attention from the academic community.
Establishing the Validity of Combination Therapy with Immune Checkpoint Inhibitors
These study results provide strong scientific evidence for the development of combination therapies with immune checkpoint inhibitors (ICIs). This is because stereotactic radiotherapy can convert "cold" tumors, which are difficult for immune cells to penetrate, into "hot" tumors with active immune responses. In the context of large-scale phase 3 clinical trials, such as AstraZeneca's 'PACIFIC-4' and Merck's 'KEYNOTE-867', which are combination clinical trials with Durvalumab and Pembrolizumab, respectively, and are facing difficulties in demonstrating efficacy, this study provides clues for the optimal timing of combination therapy and the selection of biomarkers.
Paradigm Shift in the Lung Cancer Treatment Market and VC Prospects
The market for stereotactic radiotherapy (SBRT/SABR) for early-stage non-small cell lung cancer is projected to grow rapidly from $1.4 billion in 2024 to $2.9 billion in 2030, with an annual growth rate of 8.5%. From the perspective of venture capital (VC) and investors, this research can be used to evaluate the value of next-generation immuno-oncology pipelines that can synergize with the radiation equipment market. In particular, biotech companies that possess precision medicine platform technologies that administer immune checkpoint inhibitors in conjunction with the appropriate timing of antigen release after radiation and the T-cell activation cycle are likely to benefit from long-term investment.
This pilot clinical trial (NCT03603002) administered stereotactic radiotherapy (SABR) monotherapy at a dose of 48-50 Gy to six patients with stage I non-small cell lung cancer, demonstrating the expansion of tumor-specific T-cell clones and precisely elucidating the biological mechanism of immuno-oncology combination therapy. This provides important criteria for combination administration timing and biomarker analysis for the design of large-scale phase 3 clinical trials by global pharmaceutical companies, such as AstraZeneca's 'PACIFIC-4' using Durvalumab and Merck's 'KEYNOTE-867' using Pembrolizumab. From an investor's perspective, it serves as a key indicator for evaluating the pipeline value of biotech companies located at the intersection of the stereotactic radiotherapy market, which is expected to grow to $2.9 billion by 2030, and the NSCLC treatment market, which is worth $33 billion. In the short term, it will promote research on additional immune modulators that can compensate for the temporary limitations of radiation-induced immune responses, and in the medium to long term, it is expected to lead a paradigm shift in the standard of care for early-stage lung cancer from surgery to radiation-immunotherapy combination therapy.
Source: ClinicalTrials.gov (api_ct)